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Aggressive pituitary lesion with 
a remarkably high Ki-67
Lesão pituitária agressiva com Ki-67 notavelmente elevado
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SUMMARY
The uncommon aggressive pituitary tumors are named carcinomas when metastases are de-
tected, either in the central nervous system and/or systemically. Some cases are associated 
with hormonal overproduction, but most are diagnosed because of local symptoms. These ne-
oplasias are generally refractory to current treatments. A 51 year-old woman presented sudden 
onset of headache, left arm paresis and left facial hypoesthesia. Computed tomography scan 
and magnetic resonance imaging revealed a pituitary tumor invading the left sphenoidal and 
cavernous sinuses. Laboratory data excluded hormonal hypersecretion. The patient underwent 
transsphenoidal surgery and histological findings showed a neoplasia with Ki-67 estimated at 
75%. Medical imaging excluded both a primary occult tumor and central nervous system or 
systemic dissemination. Three weeks postoperatively, neurological condition worsened, with 
new onset of ataxia, bilateral ptosis, ophthalmoplegia and an increase in the size of the lesion, 
leading to surgical intervention by craniotomy, followed by only a few sessions of radiotherapy, 
because of severe disease progression. Patient died nearly 2 months after the initial manifesta-
tions. This case illustrates the aggressiveness of some pituitary lesions, the limited efficacy of 
current treatment modalities such as surgery or radiotherapy and the pitfalls of the current pitui-
tary tumors classification. To our knowledge, this case corresponds to one of the most aggres-
sive pituitary neoplasms reported so far, with a very high Ki-67 index (75%) and short survival 
(2 months). Ki-67 index could be of prognostic value in pituitary tumors. Pituitary tumors World 
Health Organization (WHO) classification could be revisited. Arq Bras Endocrinol Metab. 2014;58(6):656-60
SUMÁRIO
Os raros tumores pituitários agressivos são chamados carcinomas quando são detectadas me-
tástases, sejam sistêmicas e/ou em sistema nervoso central. Alguns casos estão associados 
com superprodução de hormônio, mas a maioria é diagnosticada em função dos sintomas 
locais. Essas neoplasias são geralmente refratárias aos tratamentos atuais. Uma mulher com 
51 anos de idade apresentou dor de cabeça de início súbito, paralisia de braço esquerdo e 
hipoes tesia facial esquerda. A tomografia e a ressonância magnética revelaram um tumor pi-
tuitário invadindo os seios esfenoidal e cavernoso esquerdos. Os dados laboratoriais excluíram 
hipersecreção hormonal. A paciente foi submetida à cirurgia transesfenoidal, e os achados his-
tológicos mostraram uma neoplasia com Ki-67 estimado em 75%. As imagens excluíram tanto 
um tumor oculto primário quanto disseminação sistêmica ou do sistema nervoso central. Três 
semanas após a cirurgia, a condição neurológica apresentou piora com início de ataxia, ptose 
bilateral, oftalmoplegia e aumento do tamanho da lesão, levando à intervenção cirúrgica por 
craniotomia, seguida por apenas algumas sessões de radioterapia devido à progressão grave 
da doença. A paciente veio a óbito depois de quase dois meses das manifestações iniciais. O 
caso ilustra a agressividade de algumas lesões pituitárias, a eficácia limitada das modalidades 
atuais de tratamento, como a cirurgia ou a radioterapia, e as limitações da classificação atual de 
tumores pituitários. Até onde sabemos, esse caso corresponde a uma das neoplasias pituitárias 
mais agressivas descritas até hoje, com um nível muito alto de Ki-67 (75%) e sobrevida curta (2 
meses). O nível de Ki-67 pode ser de valor prognóstico em tumores pituitários. A classificação 
da Organização Mundial da Saúde (OMS) para tumores pituitários deveria ser revisitada. Arq Bras 
Endocrinol Metab. 2014;58(6):656-60
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INTRODUCTION
P ituitary tumors account for approximately 15% of all intracranial neoplasms (1,2). The majority is 
benign, non-invasive and asymptomatic. Some are de-
tected incidentally by imaging exams; others are func-
tioning-tumors generating hormonal syndromes (de-
creasing ordered: prolactin; ACTH; GH; TSH; LH), 
whereas others are suspected due to local mass symp-
toms. Hypopituitarism can also occur in some cases, 
particularly in larger tumors (3).
Pituitary carcinomas are rare conditions, accounting 
only 0.1 to 0.2% of all pituitary tumors (4,5). Pituitary 
carcinoma is defined by the presence of craniospinal 
and/or systemic metastases (6,7). There is no gender 
preference and mean of age at diagnosis is 44 years 
(4). Most pituitary carcinomas develop from invasive 
relapsing or previously operated or irradiated invasive 
adenomas (8,9). Type and grade of invasiveness do 
not represent a criteria for malignancy, although when 
prominent increase its probability (4,10). For some, 
proliferation indexes particularly Ki-67, have important 
prognostic value and should be considered as diagnos-
tic criteria (10-12). Pituitary metastatic disease, typi-
cally from breast or lung cancer, accounts for 1 to 2% of 
sellar masses and its differential diagnosis with pituitary 
tumors is challenging as they often mimic them clini-
cally, imagiologically and histologically (13,14).
We present a rare case of pituitary neoplasm with 
extremely aggressive behavior, illustrating the pitfalls 
and difficulties in the classification and management of 
these entities.
CASE REPORT
A Caucasian 51 year-old woman, non-smoker, with ir-
relevant past medical history, not taking any medica-
tion, was asymptomatic until February 2012, when she 
reported sudden onset of intense headache associated 
with left arm paresis and left facial hypoesthesia. Neu-
rological examination identified a minor left arm pare-
sis, left facial hypoesthesia and slight left upper-lid pto-
sis; no visual impairment or other neurological defects 
were observed. Computed tomography (CT) scan and 
magnetic resonance imaging (MRI) documented a pi-
tuitary mass invading the sphenoidal and left cavernous 
sinuses, and the pituitary stalk was centered (Figure 1). 
Laboratory data was significant for mild hyponatre-
mia (130 mmol/L), high creatine kinase (1,188 u/L), 
central hypothyroidism (TSH = 0.05 uUI/mL [0.34-
5.60]; free-T4 = 0.51 ng/dL [0.61-1.12]) and adrenal 
insufficiency (ACTH not measured but serum cortisol 
= 1.5 ug/dL [6.7 - 22.6]). Serum prolactin was 27.9 
ng/mL (2.74-19.64); GH was 0.447 ng/mL (0.01-
3.607) and beta-hCG < 0.5 mUI/mL (< 0.5-2.9). LH 
and FSH were not measured. 
The patient was submitted to transsphenoidal sur-
gery. A tumor with a soft consistence and necrotic com-
ponent of the pituitary apoplexy type was found and 
partially resected. Clinical improvement was observed 
after surgery, particularly on the intensity of the hea-
daches, but the third left cranial nerve palsy persisted. 
Patient was discharged under replacement therapy with 
levothyroxine and hydrocortisone. 
Histological findings revealed a monotonous hyper-
cellular population of cohesive small round cells, with 
large nuclei and prominent nucleoli. Numerous mitotic 
and apoptotic figures were seen, as well as diffuse necro-
tic areas. Ki-67 index was estimated at 75%. Immuno-
histochemistry was positive for AE1/AE3 cytokeratines, 
nuclear p53 protein, cyclin D1 and focally positive for 
synaptophysin, chromogranin, neuron-specific enolase, 
CD 56 and epithelial membrane antigen. There was no 
immunoreactivity for pituitary hormones, melanoma 
markers (S-100, HMB45, MelanA), cytokeratines 7, 8, 
18, 19, 20, thyroid transcription factor-1, CD38, CD45, 
CD30, CD117, vimentin and desmin (Figure 2). Fluo-
rescence In Situ Hybridization (FISH) molecular analy-
sis was performed for c-MYC and EWS genes showing 
normal c-MYC and EWS gene copies in 98% and 91% of 
the nuclei, respectively, with no rearrangements.
Pituitary metastization from an occult tumor or sys-
temic secondary lesions from pituitary tumor were ru-
led out by several complementary exams which included 
mammography; breast, pelvic and thyroid ultrasound; 
whole-body CT scan and 18F-Fluorodeoxyglucose Po-
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Figure 2. Pituitary carcinoma photomicrographs: A: hypercellular neoplasia with extensive necrotic areas (hematoxylin-eosin stain, 20x). B: small round 
cells with visible high mitotic activity (hematoxylin-eosin stain, 40x). C: immunohistochemistry for Ki67 protein using antibody MIB-1 quantification (20x). 
D: immunohistochemistry for AE1/AE3 cytokeratines (40x). E: Immunohistochemistry for p53 protein (40x). F: immunohistochemistry for Synaptophysin 
(40x). G: immunohistochemistry for Cyclin D1 (20x). 
Figure 3. Follow-up magnetic resonance imaging, approximately one month after the transsphenoidal surgery (March 2012): sagittal (A), coronal (B) 
views and magnetic resonance angiography (C). 
sitron Emission Tomography (18F-FDG-PET). Serum 
tumoral markers were within normal values (Carcino-
embryonic Antigen; Carcinoma Antigens 15.3/19.9; 
CYFRA 21.1; chromogranin A, calcitonin). An Ear-
-Nose-Throat specialist biopsied a non-suspicious pro-
minence in the posterior wall of cavum, which was ne-
gative for neoplasia. 
Three weeks postoperatively headaches recurred 
associated with vomiting and neurological complaints 
(ataxic gait, ophthalmoplegia and bilateral ptosis); no 
visual field defects were present and fundoscopy was 
normal. Postoperatively, hypopituitarism persisted with 
undetectable ACTH, TSH, LH, GH and low IGF-1. 
CT scan at that time, showed a pituitary mass with 
supra-sellar and lateral extension, touching the optic 
chiasm and involving the left cavernous sinus and tem-
poral lobe; no compressive effect in the brain stem or 
anomalies in the cerebral parenchyma were detected. 
Angio-MRI demonstrated a reduction in internal caro-
tids caliber but maintained patency (Figure 3).
The patient was reoperated by frontal craniotomy 
with subtotal resection of the neoplasia. Intraoperative-
ly, the tumor involved the optic nerves and infiltrated 
diffusely the adjacent structures. Histological findings 
were similar to the previous one and were consistent 
with undifferentiated small cell carcinoma (Figure 2). 
Postoperatively CT scan and MRI showed significant 
increase of the sellar mass, with prepontine extension 
and extensive invasion of the left orbit (Figures 4 and 
5). Radiotherapy was initiated but discontinued after a 
few sessions because of severe disease progression. Ra-
pid clinical deterioration did not allow palliative che-
motherapy and the patient died a few days later, appro-
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or other secondary lesions, we highlight the 18F-FDG-
-PET scan, which was negative for hypermetabolic sys-
temic lesions eventually related with the pituitary mass 
of the patient. Moreover, as many authors describe, it is 
possible that metastatic invasive pituitary macroadeno-
mas have silent and non-evident metastases, misleading 
the carcinoma diagnosis (4). In fact, autopsy studies of 
pituitary tumors patients revealed unknown metastases 
in some (4,10). On the other hand, the fatal course 
of these neoplasms do not allow the development of 
metastases, which some describe to occur in months or 
even years later (4,5,9). The most frequent metastatic 
locations includes brain (35%) and spinal cord (17%), 
followed by bone (14%), lymph nodes (12%), liver 
(10%) and lungs (6%) (9).
Pathology has a central role to the diagnosis of pi-
tuitary lesions. At present, there are no histological, im-
munochemical or ultrastructural markers that separate 
conclusively pituitary carcinoma from adenoma (15). 
In this case, many immunohistochemistry tests were 
used to exclude entities like lymphoproliferative disor-
der, melanoma, sarcoma, nasopharyngeal carcinoma, 
primitive neuroectodermal tumors, Ewing sarcoma; 
genetic analysis for c-MYC and EWS also contribute to 
rule out more convincingly lymphomas, solid tumors 
(like breast cancer) or central/peripheric primitive neu-
roectodermal tumors, respectively (16). So, at last, this 
case would fit pathologically the diagnosis of carcinoma 
of a small cell subtype from pituitary origin. ___
The protein Ki-67 is a cell proliferation marker (17) 
detected by the monoclonal antibody MIB-1 and is 
expressed as a percentage of immunopositive nuclei in 
the form of a Ki-67 proliferation index (18). Literature 
describes a mean Ki-67 for pituitary carcinomas around 
12% (± 14) (4,5,9). Thapar and cols. reported a Ki-
67 index of 1.37%, 4.66% and 11.91% in noninvasive 
adenomas, invasive adenomas and carcinomas, respec-
tively (11). Ki-67 over 10% is already criteria to admit 
pituitary carcinoma for some authors (4,10,11). In our 
patient Ki-67 was estimated at 75%, one of the highest 
so far described, which predicted an unfavorable course 
and high probability of unsuccessful treatment, as seen.
About 90% of pituitary adenomas are operated by 
transsphenoidal route and a. transcranial approach is 
usually reserved for cases with significant suprasellar, 
parasellar, retrosellar and/or subfrontal tumoral exten-
sion (19). In this case, surgery as well as radiotherapy 
failed to control disease progression. Chemotherapy, 
such as temozolomide (20), was not attempted in the 
Agressive pituitary lesion
Figure 4. Follow-up magnetic resonance imaging after the second 
surgery and before radiotherapy, approximately 2 months after 
presentation (April 2012): coronal (A,C), axial (B) and sagittal (D) views. 
DISCUSSION
This case report illustrates the diagnostic, therapeutic 
complexity and pitfalls that may characterize some pi-
tuitary lesions. In spite of the fact that a fulminant cli-
nical course and histological findings strongly suggest 
a malignant diagnosis, the case did not fulfill the diag-
nostic criteria of pituitary carcinoma according with 
WHO classification (6), because there was no evidence 
of systemic or craniospinal metastization. However, the 
course of the disease was highly aggressive and rapi-
dly progressive, despite two surgeries and radiotherapy, 
leading to death in approximately 2 months after the 
initial clinical manifestations. In addition, several his-
tological findings (high Ki-67 proliferative index and 
p53 protein immunostaining) suggested a carcinoma 
and extensive tests excluded other differential diagnosis 
of primary or secondary pathology of sellar region (12-
14). Nonetheless, a metastatic lesion from a primary 
occult tumor cannot be definitively excluded, although 
the negativity of 18F-FDG-PET scan and the absence 
of other metastatic lesions makes such a diagnosis very 
unlikely.
As referred, craniospinal/systemic metastization 
were not documented which represent its inexistence or 
misdetection by imaging procedures. Among the exa-
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patient because of low performance status and severe 
disease progression. 
We present an exceptionally rare case of pituitary le-
sion that clearly illustrates the paradox and pitfalls betwe-
en histological classifications and clinical behavior. This 
case report is a paradigm of the aggressiveness of some 
pituitary lesions. In our opinion, the WHO pituitary tu-
mors classification (6) should be revisited and the criteria 
for pituitary carcinoma diagnosis could be revisited. 
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